Long-term therapy of chronic hepatitis B with lamivudine

Hepatology

Volumn 32, Issue 4 I, 2000, Pages 828-834

  Lau, Daryl T ^a   Farooq Khokhar, M ^a   Doo, Edward ^a   Ghany, Marc G ^a   Herion, David ^a   Park, Yoon ^a   Kleiner, David E ^b   Schmid, Peter ^c   Condreay, Lynn D ^d   Gauthier, Josée ^d   Kuhns, Mary C ^e   Jake Liang, T ^a   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c National Genetics Institute   (United States)

^d GLAXOSMITHKLINE   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; FAMCICLOVIR; FIALURIDINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER HISTOLOGY; LONG TERM CARE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIRUS GENE; VIRUS RESISTANCE;

EID: 0033802362     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.17912     Document Type: Article

References (39)

1. The epidemiology of viral hepatitis in the United States
2. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan
3. Treatment of chronic viral hepatitis
4. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
5. Long-term follow-up of HBeAg positive patients with chronic active hepatitis after α-interferon therapy
6. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa
7. A preliminary trial of lamivudine for chronic hepatitis B infection
8. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
9. A one-year trial of lamivudine for chronic hepatitis B
10. Lamivudine as initial treatment for chronic hepatitis B in the United States
11. Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
12. Hepatitis B reactivation after lamivudine
13. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
14. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
15. Mutation in the HBV RNA dependent DNA polymerase confers resistance of lamivudine in vivo
16. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
17. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
18. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV and HIV
19. Performance of automated chemiluminescent paramagnetic microparticle immunoassays for HBsAg, HBsAb, and HBcAb on the Abbott i2000 system
20. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
21. Line probe assay for the detection of hepatitis B and C virus genotypes
22. Classification of chronic hepatitis: Diagnosis, grading and staging
23. Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multicentre study in Asia
24. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine
25. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group
26. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
27. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients
28. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3'thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
29. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis
30. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
31. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials
32. Efficacy of long-term lamivudine monotherapy in HBeAg negative chronic hepatitis B
33. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
34. A placebo-controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patients with chronic hepatitis B infection
35. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
36. Adefovir dipivoxil treatment of hepatitis B virus disease in patients failing lamivudine therapy
37. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
38. Use of 2'-fluoro-5-methyl-B-L-arabinofuranosyl-uracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus
39. Antiviral B-L-2'-deosynucleosides specific for hepatitis B virus infection